Kadmon competitors

Michael Cola joined Medgenics as President and CEO in September 2013. Prior to joining Medgenics, Mr. Cola served as President of Specialty Pharmaceuticals at Shire plc, a global specialty pharmaceutical company, from 2007 until April 2012. He joined Shire in 2005 as EVP of Global Therapeutic Business Units and Portfolio Management. Prior to joining Shire, he was with Safeguard Scientifics, Inc., a growth capital provider to life sciences and technology companies, where he served as President of the Life Sciences Group. While at Safeguard, Mr. Cola served as Chairman and CEO of Clarient, Inc., a cancer diagnostics company subsequently acquired by GE Healthcare, and as Chairman of Laureate Pharma, Inc., a full-service contract manufacturing organization serving research-based biologics companies. Prior to Safeguard Scientifics, Mr. Cola held senior positions in product development and commercialization at AstraMerck, a top 20 U.S. pharmaceutical company, and at AstraZeneca, a global biopharmaceutical company. Mr. Cola received a B.A. in biology and physics from Ursinus College and an M.S. in biomedical science from Drexel University. He serves on the Board of Directors of Vanda Pharmaceuticals Inc., Sage Therapeutics, Ben Franklin Technology Partners and Pennsylvania BIO, the statewide association representing the bioscience community. He also currently serves as Chairman of the Board of Governors of the Boys & Girls Clubs of Philadelphia.

Evan Loh works at PARATEK PHARMACEUTICALS, INC. and a President, COO & CMO at PARATEK PHARMACEUTICALS, INC. and is based in Merion Station, Pennsylvania.

Scott Huennekens has served as President and Chief Executive Officer since April 2002. From January 2000 to March 2002, he served as the President and Chief Executive Officer of Digirad Corporation, a medical imaging company. Mr. Huennekens is a member of the Board of Directors for Volcano Corporation, Uptake Medical, the Medical Device Manufacturers Association (MDMA), and BIOCOM. He received a B.S. in Business Administration from the University of Southern California and an M.B.A. from Harvard Business School.

Kenneth Waggoner has almost four decades of experience in management, business, operations and law. Kenneth started his career as an attorney in private practice. Notably he was a senior partner with Brobeck, Phleger and Harrison, named one of the top two law firms worldwide that provide services to biotechnology clients including Chiron, Amgen, Biogen Idec, Sangamo, Ligand, DepoTech and many others. He was the Managing Partner of Brobeck’s Los Angeles office. Kenneth was also a member of the Executive Committee for almost ten years and on the Policy Committee for numerous years managing Brobeck’s worldwide operations with annual revenues in excess of $750,000,000. While at Brobeck, Waggoner was the Co-Chairman of Brobeck’s world-wide Environmental Law Group. Further highlights of Waggoner’s career include leadership and legal positions with several start-up companies during the last several years as well as working with Fortune 500 companies most of his professional career. During his tenure with Chevron, Kenneth served as the Vice President and General Counsel of its Global Downstream operations where he was responsible for the overall management of legal services to the North American, Latin American, Europe and Asian Products Companies. At Chevron he led a successful restructuring of the company’s international Legal Department following Chevron’s acquisition of Texaco. Kenneth received his Juris Doctorate. with honors in 1973 from Loyola University School of Law in Los Angeles.

CEO of @EvofemBio. Founding CEO of @WCG_cares. Champion for women all over the world. Published author, keynote speaker and mother.